Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; and REBORN for the treatment of breakthrough cancer pain. It also develops novel prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acut… Read more
Tetra Bio-Pharma Inc. (TBPMQ) - Total Liabilities
Latest total liabilities as of August 2022: $8.93 Million USD
Based on the latest financial reports, Tetra Bio-Pharma Inc. (TBPMQ) has total liabilities worth $8.93 Million USD as of August 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tetra Bio-Pharma Inc. - Total Liabilities Trend (2019–2021)
This chart illustrates how Tetra Bio-Pharma Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tetra Bio-Pharma Inc. Competitors by Total Liabilities
The table below lists competitors of Tetra Bio-Pharma Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EVOLUTION MIN
MU:WE7
|
Germany | €4.68 Billion |
|
Pioneer High Income Closed Fund
NYSE:PHT
|
USA | $116.53 Million |
|
VHABW
PINK:VHABW
|
USA | $1.83 Million |
|
Cemex SAB de CV
STU:CEXA
|
Germany | €15.94 Billion |
|
XPS Pensions Group PLC
LSE:XPS
|
UK | GBX153.31 Million |
|
CI Com SA
SW:CIE
|
Switzerland | CHF11.88 Million |
Liability Composition Analysis (2019–2021)
This chart breaks down Tetra Bio-Pharma Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tetra Bio-Pharma Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tetra Bio-Pharma Inc. (2019–2021)
The table below shows the annual total liabilities of Tetra Bio-Pharma Inc. from 2019 to 2021.
| Year | Total Liabilities | Change |
|---|---|---|
| 2021-11-30 | $7.30 Million | +8.18% |
| 2020-11-30 | $6.75 Million | +72.36% |
| 2019-11-30 | $3.92 Million | -- |